Zuclopenthixol dihydrochloride for schizophrenia

Schizophrenia Bulletin

Volumn 35, Issue 5, 2009, Pages 855-856

  Kumar, Ajit ^a,c   Strech, Daniel ^b  

^a LEEDS AND YORK PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Balm House ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE; SULPIRIDE; ZUCLOPENTHIXOL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; ISOMERISM; MENTAL HEALTH; MOTOR DYSFUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOPENTHIXOL; DYSKINESIA, DRUG-INDUCED; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE;

EID: 69249092957     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp077     Document Type: Short Survey

References (1)

1. Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev. 2005;4:CD005474.